Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.

@article{Rizvi2008PhaseIT,
  title={Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.},
  author={Naiyer A Rizvi and Gregory J Riely and Christopher Azzoli and Vincent A. Miller and Kenneth K. W. Ng and John Fiore and Gloria Chia and Martin Brower and Robert T. Heelan and Michael J. Hawkins and Mark G. Kris},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2008},
  volume={26 4},
  pages={
          639-43
        }
}
PURPOSE Nanoparticle albumin-bound paclitaxel (NAB-paclitaxel) is an albumin-bound formulation of paclitaxel that has demonstrated improved efficacy compared with paclitaxel in the treatment of metastatic breast cancer. We undertook this trial to determine the maximum-tolerated dose (MTD) and single-agent activity of NAB-paclitaxel administered on a weekly basis to patients with stage IV non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS This was an open-label, single-arm, phase I/II… CONTINUE READING
Highly Cited
This paper has 57 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 38 extracted citations

A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion

Cancer Chemotherapy and Pharmacology • 2011
View 4 Excerpts
Highly Influenced

Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced non-small-cell lung cancer.

Chinese journal of cancer research = Chung-kuo yen cheng yen chiu • 2013
View 12 Excerpts
Highly Influenced

57 Citations

05'10'13'16'19
Citations per Year
Semantic Scholar estimates that this publication has 57 citations based on the available data.

See our FAQ for additional information.